Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of oral ozanimod in moderately to severely active Crohn's disease
NL-OMON58719Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ozanimod in Crohn's disease, sponsored by Celgene Corporation. Started Nov 2018; status: completed.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON58719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58719.